Insilico Medicine Reports 40% Response Rate at 130 mg Dose in Early Mesothelioma Trial

• Insilico Medicine reported preliminary Phase I results for ISM6331, an AI-designed oral pan-TEAD inhibitor, in a 36-patient advanced solid-tumor trial.
• At the Aug. 14, 2026, cutoff, the objective response rate among evaluable mesothelioma patients receiving 130 mg daily was 40%.
• Across 30–130 mg, mesothelioma response and disease control rates were 18.2% and 68.2%, respectively, at the first tumor assessment.
• No dose-limiting toxicity occurred across 15–130 mg; treatment-related adverse events caused no permanent discontinuations.
• Three of four partial responses remained ongoing at the cutoff, including one lasting approximately one year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261027-12383808), on October 27, 2026, and is solely responsible for the information contained therein.